EMA revises product information templates to better explain benefit-risk; implementation plan issued
This article was originally published in SRA
The European Medicines Agency has updated its product information templates for human medicines to make it easier for patients and healthcare professionals to understand the benefits and risks of a drug1.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.